Biodexa Pharmaceuticals (BDRX) announces that the Company has been formally notified that the Nasdaq Hearings Panel of the Nasdaq Stock Marketdetermined that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received notice from Nasdaq on August 27, 2024, informing the Company that it was not in compliance with the Minimum Bid Price Requirement. On October 14, 2024, the Panel granted the Company’s request for an exception to demonstrate compliance with the Minimum Bid Price Requirement for continued listing through October 31, 2024. The Company remains subject to a discretionary panel monitor through February 24, 2025, and is required to provide prompt notification during this exception period of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BDRX:
- Biodexa Pharmaceuticals Plans Strategic Share Value Adjustment
- Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod
- Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study
- Biodexa Pharmaceuticals PLC-ADR trading resumes
- Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
